Under construction – not a live service
Sign in
Taking people in CanadaPhase 4

Single Dose of Antenatal Corticosteroids for Pregnancies at Risk of Preterm Delivery (SNACS)

Key facts

Where
Calgary, Edmonton, Fredericton, Halifax, Hamilton, Kingston, London, Moncton, Montreal, New Westminster, Ottawa, Québec, Saskatoon, Sherbrooke, St. John's, Surrey, Toronto, Vancouver, Victoria, and Winnipeg, CanadaSee the 25 sites
Phase
Phase 4

Could this be for you?

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 55 years old?

Source: NCT05114096, who can take part

Where in Canada

  • University of Calgary Cumming School of MedicineCalgary, CanadaTaking people
  • Alberta Health Services; University of AlbertaEdmonton, CanadaTaking people
  • Dr. Everett Chalmers Regional HospitalFredericton, CanadaTaking people
  • Dalhousie University; Izaak Walton Killam HealthHalifax, CanadaTaking people
  • McMaster UniversityHamilton, CanadaTaking people
  • Queen's University, Kingston General Hospital Health Sciences CentreKingston, CanadaTaking people
  • Western University; London Health Sciences Centre, Victoria HospitalLondon, CanadaTaking people
  • The Moncton Hospital, Horizon Health NetworkMoncton, CanadaTaking people
  • Hopital Maisonneuve Rosemont, CIUSSS de l'est de l'Ile de MontréalMontreal, CanadaTaking people
  • McGill University, McGill University Health Center, Royal Victoria HospitalMontreal, CanadaTaking people
  • Sir Mortimer B Davis Jewish General Hospital/McGill UniversityMontreal, CanadaNot yet recruiting
  • The Centre Hospitalier Universitaire Sainte-Justine, Université de MontréalMontreal, CanadaTaking people
  • Royal Columbian HospitalNew Westminster, CanadaNot yet recruiting
  • University of Ottawa; The Ottawa HospitalOttawa, CanadaTaking people
  • Université Laval, Centre de recherche du CHU de QuébecQuébec, CanadaTaking people
  • University of Saskatchewan, Regina General HospitalSaskatoon, CanadaNot yet recruiting
  • (CIUSSS de l'Estrie-CHUS); Université de SherbrookeSherbrooke, CanadaTaking people
  • Memorial University, Eastern HealthSt. John's, CanadaNot yet recruiting
  • Fraser Health, University of British Columbia; Jim Pattison Outpatient Care and Surgery CentreSurrey, CanadaNot yet recruiting
  • Mount Sinai HospitalToronto, CanadaTaking people
  • Sunnybrook Health Sciences CenterToronto, CanadaTaking people
  • University of British Columbia; BC Women's HospitalVancouver, CanadaNot yet recruiting
  • Victoria General HospitalVictoria, CanadaNot yet recruiting
  • University of Manitoba, Health Sciences CentreWinnipeg, CanadaNot yet recruiting
  • University of Manitoba; St. Boniface General HospitalWinnipeg, CanadaNot yet recruiting

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?
Print a page for my doctor

Trial details

Who runs it
McMaster University
Trial code
NCT05114096
Record updated
7 January 2026
Original description
Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.Read full original descriptionShow less

Single Dose of Antenatal Corticosteroids (SNACS) Randomized Controlled Trial for Pregnancies at Risk of Preterm Delivery: To Keep Babies and Children Safe

Antenatal corticosteroids (ACS) reduce the risks of neonatal death and morbidities in preterm infants, such as respiratory distress syndrome.

The standard of care for pregnant people at risk of preterm birth includes 2 doses of Celestone (for a total of 24 mg in Canada, or 22.8 mg in Australia) to accelerate fetal lung maturity.

The investigators plan to conduct a randomized controlled trial to determine whether half the usual dose (12 mg in Canada, or 11.4 mg in Australia) of Celestone is non-inferior to the standard double doses.

Inclusion: Pregnant people, aged 18 to 55 years old, at risk of preterm birth with a singleton or twins between 22 weeks and 0 days and <34 weeks and 6 days gestation who have received only a single dose of Celestone within 24 hours; Capable of giving informed, written consent.

Exclusion: Contraindication to corticosteroids; Previous participation in this trial (in a previous pregnancy); Systemic corticosteroids for medical conditions during the pregnancy (e.g. lupus, severe asthma, Covid, etc); Known severe/life-threatening fetal or pregnant patient condition (e.g. fetal congenital/chromosomal abnormality); Demise of one or more fetuses after 14 weeks and 0 days.

ClinicalTrials.gov NCT05114096